Glucotrack (Nasdaq:GCTK) announced today that it intends to participate in a bionic pancreas initiative in Europe.

(Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that ...

today announced that safety and performance data from its first-in-human trial of its long-term continuous blood glucose monitoring (CBGM) syste Leading diabetes researcher and clinician joins ...

approval for continuous blood glucose monitoring (CBGM) technology from FDA expected in Q4 2025 Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack ...

Phantom Neuro announced today that it raised $19 million in a Series A funding round to support its neural interface technology. Ottobock, a major company in the fields of prosthetics, orthotics ...